Ra Capital Management, L.P. - Jun 18, 2025 Form 4 Insider Report for Cidara Therapeutics, Inc. (CDTX)

Role
Director
Signature
/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
Stock symbol
CDTX
Transactions as of
Jun 18, 2025
Transactions value $
$0
Form type
4
Date filed
6/18/2025, 05:20 PM
Previous filing
Jun 20, 2025
Next filing
Jun 26, 2025
SEC
View on sec.gov

Reporting Owners (4)

Name Relationship Address Signature Signature date CIK
RA CAPITAL MANAGEMENT, L.P. Director 200 BERKELEY STREET, 18TH FLOOR, BOSTON /s/ Peter Kolchinsky, Manager of RA Capital Management, L.P. 2025-06-18 0001346824
RA Capital Healthcare Fund LP Director 200 BERKELEY STREET, 18TH FLOOR, BOSTON /s/ Peter Kolchinsky, Manager of RA Capital Healthcare Fund GP, LLC the General Partner of RA Capital Healthcare Fund, L.P. 2025-06-18 0001315082
Kolchinsky Peter Director C/O RA CAPITAL MANAGEMENT, L.P., 200 BERKELEY STREET, 18TH FLOOR, BOSTON /s/ Peter Kolchinsky, individually 2025-06-18 0001384859
Shah Rajeev M. Director C/O RA CAPITAL MANAGEMENT, L.P., 200 BERKELEY STREET, 18TH FLOOR, BOSTON /s/ Rajeev Shah, individually 2025-06-18 0001619841

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CDTX Stock Option (right to buy) Award $0 +5.08K $0.00 5.08K Jun 18, 2025 Common Stock 5.08K $21.31 See Footnotes F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the grant of an annual director stock option to Joshua Resnick pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy of 11,100 shares pro-rated based on the number of days Dr. Resnick has served on the Issuer's Board of Directors prior to the grant date divided by 365 days.
F2 The shares subject to the option shall vest on the earlier of (i) June 18, 2026 or (ii) the day prior to the date of the Issuer's 2026 annual meeting of stockholders.
F3 RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
F4 Joshua Resnick is a Partner of the Adviser who serves on the Issuer's board of directors. Under Dr. Resnick's arrangement with the Adviser, Dr. Resnick holds the option for the benefit of the Fund. Dr. Resnick is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.

Remarks:

Joshua Resnick, a Partner of the Adviser, serves on the Issuer's board of directors.